Accuray Secures CE Mark For Accuray Helix, A CT-Guided Helical Radiotherapy System
Portfolio Pulse from Benzinga Newsdesk
Accuray has received the CE Mark for its Accuray Helix, a CT-guided helical radiotherapy system. This system targets emerging markets with limited access to advanced cancer care.
August 27, 2024 | 11:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Accuray's new Helix system, now CE Mark approved, is designed to enhance cancer treatment accessibility in emerging markets, potentially expanding the company's market reach.
The CE Mark approval for Accuray's Helix system is a significant regulatory milestone, allowing the company to market this product in Europe and other regions recognizing the CE Mark. This could lead to increased sales and market expansion, particularly in emerging markets with limited access to advanced cancer care. The news is likely to positively impact Accuray's stock price in the short term as it opens new revenue opportunities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100